APPTT
PTAC/CFTR
Margarida Amaral
FCUL-Faculty of Sciences, University of Lisboa
Vibha Lama, MD MS
Emory University, Atlanta, GA
Gianni Carraro, PhD
Cedars-Sinai Medical Center
The recent success of highly effective modulator therapies (HEMT) has transformed research in the CF field from focusing on rescuing mutant CFTR to identifying and addressing emergent challenges. A significant increase in life expectancy for individuals with CF is now accompanied by a higher predisposition to cancer (5to 7-fold vs non-CF population), as confirmed by recent large-scale studies. This presents a new challenge at the forefront of this disease.
To understand the mechanisms linking dysfunctional CFTR to carcinogenesis, we need to broaden our perspective beyond CF as merely a channelopathy and consider other cellular roles for CFTR. Besides transporting anions across epithelia, CFTR has been implicated in other functions. Indeed, it is emerging in the literature that CFTR is involved in essential cellular processes such as development, epithelial differentiation, maintenance of epithelial apical basolateral polarity, and tissue regeneration.
Another important question, relevant for gene therapy and gene editing, is identifying the "right" cells that normally express CFTR and determining whether the absence of functional CFTR disrupts the balance of epithelial cell types, particularly in the airways.
Speaker: Weam S A Shahin, MD PhD – University of Iowa
Speaker: Amirala Ostad Mohammad Nazari, BSc (he/him/his) – Department of Anatomy, Physiology and Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada
Speaker: Ruth-Love Damoah, n/a
Speaker: Saira Ahmad, PhD – Eldec Pharmaceuticals